Latest News

To determine the impact of daily shifts based on rigid registration to intraprostatic markers (IPMs) on coverage of boost doses delivered to gross nodal disease for prostate cancer. Seventy-five cone-beam CTs (CBCTs) from 15 patients treated with definitive radiation for clinically node-positive prostate cancer underwent fiducial-based and pelvic bony-based registration to the initial planning scans.

Treatment with long-term androgen deprivation therapy (ADT) and radiation therapy (RT) is the nonsurgical standard-of-care for patients with high- or very high-risk prostate cancer (HR-PC), but the optimal timing between ADT and RT initiation is unknown.

Gleason pattern 4 (GP4) quantity, invasive cribriform and/or intraductal carcinoma (IC/IDC), and presence of tertiary pattern 5 (TP5) at radical prostatectomy (RP) specimens all add in risk stratification of Grade group (GG) 2 prostate cancer patients.

Epithelial-mesenchymal transition (EMT) contributes to tumor invasion, metastasis and drug resistance. AKT activation is key in a number of cellular processes. While many positive regulators for either EMT or AKT activation have been reported, few negative regulators are established.

Clinical practice guidelines (CPGs) distil an evidence base into recommendations. CPG adherence is associated with better patient outcomes. However, preparation and dissemination of CPGs are a costly task involving multiple skilled personnel.

Cisplatin-containing combination chemotherapy has been the standard of care since the late 1980s, but the response rate is <50%. Studies have shown that the efficiency of chemotherapy differs among molecular subtypes of bladder cancer.

{{header-clinical-trials-navigation}} Protocol for the Development of a Machine Learning Model for Prostate Cancer Treatment Planning Condition: Prostate Cancer, Artificial Intelligence, Radiotherapy Study Type: Observational Clinical Trials Identifier NCT 8-digits: NCT04441775 Sponsor: Dartmouth-Hitchcock Medical Center Phase: Eligibility: Age: minimum 21 Years maximum 90 Years Gender: Male Inclusion Criteria: Favorable-risk inclusion criteria (as per RTOG 0415) 1. […]

{{header-clinical-trials-navigation}} A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03837353 Sponsor: NYU Langone Health Phase: Phase 1/Phase 2 Eligibility: Age: minimum 18 Years maximum 100 Years Gender: […]

{{header-clinical-trials-navigation}} The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening. Condition: Prostate Cancer Study Type: Observational Clinical Trials Identifier NCT 8-digits: NCT03857477 Sponsor: Institute of Cancer Research, United Kingdom Phase: Eligibility: Age: minimum 55 Years maximum 69 Years Gender: Male Inclusion Criteria: Men aged 55 to 69 years. Caucasian […]

{{header-clinical-trials-navigation}} A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer Condition: Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03637543 Sponsor: Beth Israel Deaconess Medical Center Phase: Phase 2 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Patients must have signed an informed-consent form indicating […]